



PERIMETER

Imaging Like You've Never Seen Before

Weekly IR Round-Up

#ICYMI - In Case You Missed It!

"Our commercial team is seeing growing market traction as they work to establish Perimeter S-Series OCT as a preferred technology for margin visualization in the OR.

We successfully completed three S-Series placements year to date, including two additional previously unannounced placements, one within a current national healthcare network customer and one within a new healthcare network, showing our ability to expand our customer footprint. We fielded substantial interest from our demos and interactions at the recent ASBrS conference.

In addition, we are seeing the power of peer-based recommendations, as current surgeon champions, who are already using Perimeter's technology in their operating rooms, are referring their colleagues to our sales team."



Adrian Mendes, Perimeter's Chief Executive Officer

[Q1 Results](#)

May 14, 2024

If you were unable to dial-into the live call, you can access the replay - along with links to the other quarterly materials - [on our website here](#).

The Patient Journey

At Perimeter, we aim to ensure that no patient has to go through the emotional and physical trauma of a second surgery due to cancer left behind.

Listen to Suzanne describe her cancer journey and realization that "time" is like a currency - and how we spend it is incredibly important.



Let's Stay Connected

Follow Perimeter Medical on Social!

The best way to hear the latest news from Perimeter is to follow us on one of our social media channels:

- **X** (formerly Twitter): <https://twitter.com/PerimeterMed>
- **LinkedIn**: <https://www.linkedin.com/company/perimeter-medical-imaging/>

You can also sign up to get Perimeter [news release alerts](#) delivered directly to your email or check out the news feed on our [investor website](#).

Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit www.perimetermed.com/disclosures.

For more information about Perimeter, please contact: investors@perimetermed.com

*You are receiving this email because you signed up for news alerts from Perimeter Medical Imaging AI. Please use the "**Unsubscribe Preferences**" link below if you wish to opt out of this e-newsletter.*



Perimeter Medical Imaging AI, 8585 N. Stemmons Freeway, Suite 106N, Dallas, TX 75247

[Unsubscribe Preferences](#)

[TSXV: PINK](#) | [OTC PYNKF](#) | [FSE: 4PC](#)



© 2024 Perimeter Medical Imaging AI, Inc.